OTCMKTS:CRXMGene Biotherapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gene Biotherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.04 0.00 (0.00 %) (As of 07/3/2020 11:41 AM ET) Add Compare Share Today's Range$0.03Now: $0.04▼$0.0450-Day Range$0.03MA: $0.09▼$0.1552-Week Range$0.02Now: $0.04▼$0.19Volume20,843 shsAverage Volume93,138 shsMarket Capitalization$543,375.00P/E RatioN/ADividend YieldN/ABeta1.18 ProfileAdvanced ChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Taxus Cardium Pharmaceuticals Group, Inc. manages a portfolio of medical technologies in the United States. The company engages in the development and commercialization of Generx, an angiogenic gene therapy product candidate that is in Phase III clinical trial for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It also provides Excellagen technology platform, a FDA-approved flowable dermal matrix for advanced wound care treatment, as well as serves as a delivery platform for small molecule drugs, proteins, and biologics. In addition, the company develops a medical data analytics technology platform, which offers products for the life insurance and healthcare sectors. The company was formerly known as Cardium Therapeutics, Inc. and changed its name to Taxus Cardium Pharmaceuticals Group, Inc. in March 2014. Taxus Cardium Pharmaceuticals Group, Inc. was founded in 2003 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Gene Biotherapeutics. Previous Next 2.4 Community Rank Outperform VotesGene Biotherapeutics has received 65 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGene Biotherapeutics has received 71 “underperform” votes. (Add your “underperform” vote.)Community SentimentGene Biotherapeutics has received 52.21% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Gene Biotherapeutics and other stocks. Vote “Outperform” if you believe CRXM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRXM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGene Biotherapeutics does not currently pay a dividend.Dividend GrowthGene Biotherapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gene Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders49.80% of the stock of Gene Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.68 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CRXM Previous SymbolNYSE:CXM CUSIPN/A CIK772320 Webwww.cardiumthx.com Phone858-436-1000Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees6 Outstanding Shares14,490,000Market Cap$543,375.00 Next Earnings DateN/A OptionableNot Optionable OTC:CRXM Rates by TradingView Receive CRXM News and Ratings via Email Sign-up to receive the latest news and ratings for CRXM and its competitors with MarketBeat's FREE daily newsletter. Gene Biotherapeutics (OTCMKTS:CRXM) Frequently Asked Questions How has Gene Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)? Gene Biotherapeutics' stock was trading at $0.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRXM stock has decreased by 76.6% and is now trading at $0.0375. View which stocks have been most impacted by Coronavirus. Has Gene Biotherapeutics been receiving favorable news coverage? Media stories about CRXM stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Gene Biotherapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Gene Biotherapeutics. Who are some of Gene Biotherapeutics' key competitors? Some companies that are related to Gene Biotherapeutics include Neuralstem (CUR), CytRx (CYTR), Innate Pharma (IPHA), Mymetics (MYMX) and Omni Bio Pharmaceutical (OMBP). View all competitors. What other stocks do shareholders of Gene Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gene Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), Anavex Life Sciences (AVXL), IsoRay (ISR), Protalix Biotherapeutics (PLX), Sangamo Therapeutics (SGMO), Adaptimmune Therapeutics (ADAP), IntelliPharmaCeutics Intl (IPCIF), MGT Capital Investments (MGTI) and Nokia Oyj (NOK). Who are Gene Biotherapeutics' key executives? Gene Biotherapeutics' management team includes the following people: Mr. Christopher J. Reinhard, Co-Founder, Chairman, CEO, Pres & Treasurer (Age 65)Mr. Jiayue Zhang, Exec. Chairman (Age 61)Mr. Duane Linstrom, Gen. CounselDr. Gabor M. Rubanyi, Chairman of Scientific Advisory Board & Chief Scientific Officer (Age 72)Mr. Kelly D. Scott, VP of Bus. Devel. of Medtech Bus. Unit and EVP of Inner Cool Therapies Inc (Age 63) What is Gene Biotherapeutics' stock symbol? Gene Biotherapeutics trades on the OTCMKTS under the ticker symbol "CRXM." How do I buy shares of Gene Biotherapeutics? Shares of CRXM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Gene Biotherapeutics' stock price today? One share of CRXM stock can currently be purchased for approximately $0.04. How big of a company is Gene Biotherapeutics? Gene Biotherapeutics has a market capitalization of $543,375.00. Gene Biotherapeutics employs 6 workers across the globe. What is Gene Biotherapeutics' official website? The official website for Gene Biotherapeutics is www.cardiumthx.com. How can I contact Gene Biotherapeutics? Gene Biotherapeutics' mailing address is 11568 SORRENTO VALLEY ROAD SUITE 14, SAN DIEGO CA, 92121. The company can be reached via phone at 858-436-1000 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
